Clinical Trial Detail

NCT ID NCT04419519
Title Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

CLL/SLL

chronic lymphocytic leukemia

Therapies

Venetoclax

Age Groups: adult senior

No variant requirements are available.